|
ZHEJIANG SACHEM PHARMACEUTICAL TECHNOLOGY CO., LTD
|
Since its establishment, Zhejiang Saikai Pharmaceutical Technology Co., Ltd. has continuously enhanced its resource integration ability around the pharmaceutical industry chain, built an enterprise-oriented and market-oriented business system, actively identified the key links of the upstream and downstream of the industrial chain, and promoted the overall improvement of the supply chain.
The company has always been committed to opening the international market for small and medium-sized production enterprises. Through the efforts of professional international business team, the company has helped steroid hormone apis and intermediates gain a certain market voice in India. Based on the existing achievements, the company insists on expanding the product line, and has established cooperative relations with many manufacturers in Zhejiang, Hunan, Jiangsu and other provinces. In addition to India, the products are exported to Europe, South America and other overseas regions, and a broad sales market has been established.
Since 2075, relying on the head office to carry out API import, registration and agent procurement business. Under the cooperation of the total company registration team, the company successfully completed the introduction and registration of a number of high-quality apis, and established product cooperation with foreign first-line enterprises, and successfully helped the parent company and domestic pharmaceutical customers related review.
In the future, Sikai Pharmaceutical will forge ahead, do not slack, focus on improving the level of business, to create an excellent corporate brand image. We will make full use of our own advantages, continue to integrate domestic and foreign resources, through strategic cooperation to reach a strong alliance between enterprises, to achieve mutual benefit, mutual assistance and win-win. |
Send Inquiry
|
|
SHANGHAI JINDUN INDUSTRIAL CO.,LTD
|
Bivalirudin is a kind of synthetic novel anticoagulants. It is the direct, specific and reversible inhibitor of thrombin. It was developed by the Swiss Basset (Biogen) originally. Then it was transferred to the United States Medicines Company, and approved for marketing in the United States in 2000. Its anticoagulant ingredient is a kind of 20 peptides derived from hirudin. Bivalirudin can specifically bind with catalytic site and the anion binding site of whether thrombin that is in the blood circulation or thrombus-bound thrombin, thus directly inhibiting thrombin activity. And its role is characterized by short, reversible. Early clinical studies show that the anticoagulation treatment of bivalirudin is good. And the incidence of bleeding events is low. So its use is safer than traditional heparin therapy. It is mainly used for the prevention of angioplasty interventional treatment of ischemic complications of unstable angina pectoris before and after. |
Send Inquiry
|
Pharma Sources Insight January 2025
